About InVivoSIM anti-human CD20 (Ocrelizumab Biosimilar) This non‑therapeutic biosimilar antibody uses the same variable regions as the therapeutic antibody Ocrelizumab, making it ideal for research use. Ocrelizumab is a humanized IgG1 monoclonal antibody that specifically targets CD20, a surface antigen expressed on pre-B and mature B cells but absent on stem cells and plasma cells. CD20 plays a key role in B cell activation and proliferation. By binding to CD20, Ocrelizumab mediates B cell depletion primarily through antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). This Ocrelizumab biosimilar is well suited for investigating B cell–mediated mechanisms in autoimmunity, neuroinflammation, and hematologic malignancies, as well as for exploring therapeutic B cell depletion strategies. InVivoSIM anti-human CD20 (Ocrelizumab Biosimilar) Specifications IsotypeHuman IgG1, κ Recommended Isotype Control(s)RecombiMAb human IgG1 isotype control, anti-hen egg lysozyme Recommended Dilution BufferInVivoPure pH 7.0 Dilution Buffer ImmunogenHuman CD20 Reported ApplicationsIn vivo functional assays in vitro functional assays Flow cytometry ELISA FormulationpH 7.0 Contains no stabilizers or preservatives Endotoxin≤0.5EU/mg (≤0.0005EU/μg)Determined by LAL gel clotting assay Aggregation<5% Determined by SEC Purity≥95%Determined by SDS-PAGE Sterility0.2 μm filtration ProductionPurified from cell culture supernatant in an animal-free facility PurificationProtein A Molecular Weight150 kDa StorageThe antibody solution should be stored at the stock concentration at 4°C. Do not freeze.
